-
proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural
-
was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with cancer and other serious diseases. Our novel approach to cancer treatment involves targeting the export
-
cancer immunotherapy, we combine our leading expertise in protein kinases with a uniquely targeted, scalable approach to empower the rapid design and development of transformational medicines
-
of medicinal chemistry. The candidate will be responsible for designing, synthesizing, and optimizing molecules targeting GPCRs (cannabinoid receptors; allosteric and orthosteric) and ion channels (a4b2 nAChR
-
with AI as one tool of choice, for targeted or frugal innovations to ensure resilience to compound extremes, assure clean water or air, prevent cascading failures across interconnected systems, and adapt